Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Rowan Kuiper, PhD, Mark van Duin, PhD, Martin H Van Vliet, Erik H Van Beers, PhD, Berna Berna Beverloo, PhD, Sonja Zweegman, MD PhD, Tom Cupedo, PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139987

Published: 2020

Journal Articles

Peripheral Neuropathy in the Cassiopeia Study

Cathelijne Fokkema, MD, Bronno Van Der Holt, PhD, Mark van Duin, PhD, Ruth Wester, MD, Tom Cupedo, PhD, Philippe Moreau, MD, Jessica Vermeulen, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-137400

Published: 2020

Journal Articles

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Pim Mutsaers, MD, Rowan Kuiper, MSc, Dora Hammerl, Msc, Mark van Duin, PhD, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Walter M Gregory, Jan J Cornelissen, MD PhD, Annemiek Broyl, MD PhD, Reno Debets, PhD, Pieter Sonneveld, MDPhD

Blood (2018) 132 (Supplement 1): 241.

https://doi.org/10.1182/blood-2018-99-118488

Published: 2018

Journal Articles

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Davine Hofste op Bruinink, MD MSc, Mark van Duin, PhD, Meral Beksac, MD, Christoph Driessen, MD, Heinz Ludwig, MD, Michael Vermeulen, BSc, Rowan Kuiper, MSc, Martin H van Vliet, PhD, Bronno van der Holt, PhD, Roman Hajek, MD PhD, Hans Erik Johnsen, MD Professor, Meletios A Dimopoulos, MD, Antonio Palumbo, MD, Michele Cavo, MD, Pieter Sonneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2018-99-119873

Published: 2018

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Ruth Wester, King Hong Lam, MD PhD, Mark van Duin, PhD, Suzana Couto, Yan Ren, Maria Wang, PhD, Bronno van der Holt, Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Max Qian, Anjan Thakurta, PhD, Annemiek Broyl, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3052.

https://doi.org/10.1182/blood.V130.Suppl_1.3052.3052

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma

Davine Hofste op Bruinink, MD MSc, K. Martin Kortüm, MD, Mark van Duin, PhD, Mathijs A. Sanders, PhD, Remco Hoogenboezem, MSc, Michael Vermeulen, BSc, Laura Bruins, Jonathan Ahmann, Annemiek Broijl, MD PhD, Sonja Zweegman, MD PhD, Esteban Braggio, PhD, Bronno van der Holt, PhD, A. Keith Stewart, MD PhD, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 2984.

https://doi.org/10.1182/blood.V126.23.2984.2984

Published: 2015

Journal Articles

Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma

Mark van Duin, PhD, Rowan Kuiper, BSc, Martin van Vliet, PhD, Annemiek Broijl, MD PhD, Leonie de Best, MSc, Erik van Beers, PhD, Bronno Van Der Holt, PhD, Heleen Visser-Wisselaar, PhD, Lizanne Bosman, BSc, Belinda Dumee, BSc, Fanni van den Bosch, BSc, Michael Vermeulen, BSc, Jasper Koenders, BSc, Marian Stevens-Kroef, PhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 2967.

https://doi.org/10.1182/blood.V126.23.2967.2967

Published: 2015

Journal Articles

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Isabel JF Hofman, Mark van Duin, PhD, George Mulligan, PhD, Ellen Geerdens, Emanuela Garelli, Cecilia Mancini, Heidi Lemmens, Michel Delforge, Peter Vandenberghe, MDPhD, Iwona Wlodarska, Anna Aspesi, Lucienne Michaux, Pieter Sonneveld, MD PhD, Kim De Keersmaecker

Blood (2015) 126 (23): 2969.

https://doi.org/10.1182/blood.V126.23.2969.2969

Published: 2015

Journal Articles

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

Martin H. Van Vliet, PhD, Rowan Kuiper, BSc, Belinda Dumee, BSc, Leonie de Best, MSc, Peter J. van der Spek, PhD, Emmanuel M.E.H. Lesaffre, PhD, Mark van Duin, PhD, Anders Waage, MD PhD, Sonja Zweegman, MDPhD, Pieter Sonneveld, MDPhD, Erik H. van Beers, PhD

Blood (2014) 124 (21): 2026.

https://doi.org/10.1182/blood.V124.21.2026.2026

Published: 2014

Journal Articles

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Florence Magrangeas, Rowan Kuiper, BSc, Hervé Avet-loiseau, MD PhD, Wilfried Gouraud, Catherine Guérin, Henri Der Sakissian, Jérôme Suhard, Michel Attal, Pieter Sonneveld, MDPhD, Charles Dumontet, MD PhD, Philippe Moreau, Mark van Duin, PhD, Loic Campion, MD, Stephane Minvielle

Blood (2014) 124 (21): 2057.

https://doi.org/10.1182/blood.V124.21.2057.2057

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

Annemiek Broyl, MD, Rowan Kuiper, BSc, Mark van Duin, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, Uta Bertsch, MD, Sonja Zweegman, MD, PhD, Arjan Buijs, PhD, Dirk Hose, MD, PhD, Henk Lokhorst, MD, PhD, Hartmut Goldschmidt, MD, PhD, Pieter Sonneveld, MD

Blood (2012) 120 (21): 3973.

https://doi.org/10.1182/blood.V120.21.3973.3973

Published: 2012

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Annemiek Broyl, MD, Rowan Kuiper, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Yvonne de Knegt, Bronno van der Holt, PhD, Laila el Jarari, Berna Beverloo, PhD, H. Lokhorst, Sonja Zweegman, George Mulligan, PhD, Hartmut Goldschmidt, Mark van Duin, PhD, Pieter Sonneveld

Blood (2010) 116 (21): 445.

https://doi.org/10.1182/blood.V116.21.445.445

Published: 2010

Journal Articles

MicroRNA Profiling In Multiple Myeloma

Sophie Corthals, Su Ming Sun, Rowan Kuiper, Yvonne de Knegt, Annemiek Broyl, MD, Bronno van der Holt, H. Berna Beverloo, PhD, Justine K Peeters, Mark van Duin, PhD, Henk M Lokhorst, Sonja Zweegman, Mojca Jongen-Lavrencic, MD, PhD, P. Sonneveld

Blood (2010) 116 (21): 302.

https://doi.org/10.1182/blood.V116.21.302.302

Published: 2010

Journal Articles

Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.

Annemiek Broyl, MD, Dirk Hose, MD, PhD, Yvonne de Knegt, Henk Lokhorst, MD, PhD, Hartmut Goldschmidt, MD, PhD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2007) 110 (11): 3173.

https://doi.org/10.1182/blood.V110.11.3173.3173

Published: 2007

NARROW

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Peripheral Neuropathy in the Cassiopeia Study

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma

Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

A High-Risk Survival Classifier for Multiple Myeloma

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

MicroRNA Profiling In Multiple Myeloma

Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only